Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Re-treatment of Chronic Hepatitis C after DAA failure
NCT03483987Terminated
- Sponsor
- Sanjay Gandhi Postgraduate Institute of Medical Sciences
- Start
- Feb 2018
- Primary completion
- Apr 2022
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
- Countries
- 1
01
Overview
Open-label trial of sofosbuvir, velpatasvir, daclatasvir and ledipasvir in hepatitis C (HCV), sponsored by Sanjay Gandhi Postgraduate Institute of Medical Sciences. Started Feb 2018; status: terminated.
02
Drugs
sofosbuvirvelpatasvirdaclatasvirledipasvir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT03483987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03483987.